Well, knock GTO over with a feather: we never thought we'd see the day that "RNA interference" made it into a Wall Street Journal headline. This article reports on recent results from Alnylam Pharmaceuticals' human trial for its RNAi-based drug for respiratory syncytial virus. The story quotes Alnylam CEO John Maraganore as saying, "This is really the first moonwalk for RNAi therapeutics." Michael Jackson would be so proud.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.